UK Top 10 News

Stay informed with the latest breaking news from across the UK

Swedish researchers at Karolinska Institute found that 160mg daily aspirin reduces colorectal cancer recurrence by 55% in patients with PI3K pathway mutations (37% of cases) over three years post-surgery.
The trial with 3,500 patients showed aspirin's anti-inflammatory effects, PI3K interference, and platelet dampening protect against relapse.
Prof Anna Martling called it a huge effect, urging genetic testing for targeted use.
Aspirin prevents high-risk cases but risks like bleeding exist (four adverse events in trial).
This builds on prior studies for hereditary conditions.
Colorectal cancer affects 2 million yearly, rising due to diet, inactivity, pollution.
CRUK's Dr Catherine Elliott noted need for larger studies like CaPP3 to confirm benefits for longer, cancer-free lives.
2025-09-18 17:05:00



showbiz sport money travel garden news tech health science business politics culture environment